Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Rocket Pharmaceuticals, Inc.
rocketpharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
Rocket Pharmaceuticals entered into an at-the-market offering agreement with Cantor Fitzgerald to raise up to $100 million through common stock sales, providing the company with flexible capital access for operations and development.
Key Takeaways
Rocket Pharmaceuticals secured a $100 million at-the-market offering program with Cantor Fitzgerald & Co.
The offering is supported by a Form S-3 shelf registration statement filed on March 2, 2026
2 more takeaways